HeartBeam Analyst Ratings
Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target
HeartBeam Analyst Ratings
Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target
Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target
HeartBeam Analyst Ratings
Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target
HeartBeam Analyst Ratings
Alliance Global Partners Maintains Buy on HeartBeam, Lowers Price Target to $5.55
Analysts Offer Insights on Healthcare Companies: Emergent Biosolutions (EBS) and HeartBeam (BEAT)
Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target
HeartBeam Analyst Ratings
No Data